欧洲、北美和澳大利亚抗生素暴露与早发型新生儿脓毒症分析
该回顾性横断面研究纳入2014年1月1日至2018年12月31日欧洲、北美和澳大利亚11国13个网络(医院或人群基础)中胎龄≥34周的活产儿,共757 979名。2.86%(21 703名;95%CI 2.83%-2.90%)在出生第一周接受静脉抗生素,各网络启动比例1.18%-12.45%;EOS发生率为0.49例/1000活产(范围0.18-1.45),EOS相关死亡率为3.20%(12/375;范围0.00%-12.00%)。每例EOS对应58名新生儿启动抗生素和273个抗生素日,抗生素暴露为135天/1000活产(范围54-491)。作者认为出生第一周抗生素暴露与EOS负担不成比例,国际差异高达9倍,并提出一套指标用于基准比较和未来安全减少早期抗生素暴露的干预。
要点
- 757 979名胎龄≥34周活产儿中,2.86%(21 703名;95%CI 2.83%-2.90%)在出生第一周接受静脉抗生素,各网络启动比例1.18%-12.45%。
- EOS发生率为0.49例/1000活产(范围0.18-1.45),EOS相关死亡率为3.20%(12/375;范围0.00%-12.00%)。
- 每例EOS对应58名新生儿启动抗生素和273个抗生素日;抗生素暴露为135天/1000活产(范围54-491)。
- 有EOS者抗生素疗程中位9天(IQR 7-14),无EOS者中位4天(IQR 3-6)。
- 作者认为出生第一周抗生素暴露与EOS负担不成比例,国际差异高达9倍,并提出一套指标用于基准比较和未来安全减少早期抗生素暴露的干预。
适用人群与场景
- 2014年1月1日至2018年12月31日出生、胎龄≥34周的活产儿,来自欧洲、北美和澳大利亚11国13个医院或人群基础网络。
- 暴露定义为出生第一周内启动抗生素。
研究设计与关键结果
- 研究类型:回顾性横断面研究;纳入2014年1月1日至2018年12月31日11国13个网络中胎龄≥34周的活产儿,共757 979名。
- 出生第一周接受静脉抗生素者21 703名(2.86%;95%CI 2.83%-2.90%),其中男孩12 886名(59.4%),中位胎龄39周(IQR 36-40),中位出生体重3250 g(IQR 2750-3750)。
- 各网络启动抗生素比例范围为1.18%-12.45%。
- 抗生素疗程中位:EOS患儿9天(IQR 7-14),无EOS患儿4天(IQR 3-6)。
- 抗生素暴露为135天/1000活产(各网络范围54-491天/1000活产)。
- EOS发生率为0.49例/1000活产(范围0.18-1.45例/1000活产)。
- EOS相关死亡率为3.20%(12/375;范围0.00%-12.00%)。
- 每例EOS对应58名新生儿启动抗生素和273个抗生素日。
证据类型、等级与局限
- 证据类型:回顾性横断面研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为出生第一周抗生素暴露与EOS负担不成比例,国际差异高达9倍。
- 作者提出一套报告抗生素暴露与EOS两个维度的指标,用于基准比较和未来安全减少早期抗生素暴露的干预。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Appropriate use of antibiotics is life-saving in neonatal early-onset sepsis (EOS), but overuse of antibiotics is associated with antimicrobial resistance and long-term adverse outcomes. Large international studies quantifying early-life antibiotic exposure along with EOS incidence are needed to provide a basis for future interventions aimed at safely reducing neonatal antibiotic exposure.
OBJECTIVE: To compare early postnatal exposure to antibiotics, incidence of EOS, and mortality among different networks in high-income countries.
DESIGN, SETTING, AND PARTICIPANTS: This is a retrospective, cross-sectional study of late-preterm and full-term neonates born between January 1, 2014, and December 31, 2018, in 13 hospital-based or population-based networks from 11 countries in Europe and North America and Australia. The study included all infants born alive at a gestational age greater than or equal to 34 weeks in the participating networks. Data were analyzed from October 2021 to March 2022.
EXPOSURES: Exposure to antibiotics started in the first postnatal week.
MAIN OUTCOMES AND MEASURES: The main outcomes were the proportion of late-preterm and full-term neonates receiving intravenous antibiotics, the duration of antibiotic treatment, the incidence of culture-proven EOS, and all-cause and EOS-associated mortality.
RESULTS: A total of 757 979 late-preterm and full-term neonates were born in the participating networks during the study period; 21 703 neonates (2.86%; 95% CI, 2.83%-2.90%), including 12 886 boys (59.4%) with a median (IQR) gestational age of 39 (36-40) weeks and median (IQR) birth weight of 3250 (2750-3750) g, received intravenous antibiotics during the first postnatal week. The proportion of neonates started on antibiotics ranged from 1.18% to 12.45% among networks. The median (IQR) duration of treatment was 9 (7-14) days for neonates with EOS and 4 (3-6) days for those without EOS. This led to an antibiotic exposure of 135 days per 1000 live births (range across networks, 54-491 days per 1000 live births). The incidence of EOS was 0.49 cases per 1000 live births (range, 0.18-1.45 cases per 1000 live births). EOS-associated mortality was 3.20% (12 of 375 neonates; range, 0.00%-12.00%). For each case of EOS, 58 neonates were started on antibiotics and 273 antibiotic days were administered.
CONCLUSIONS AND RELEVANCE: The findings of this study suggest that antibiotic exposure during the first postnatal week is disproportionate compared with the burden of EOS and that there are wide (up to 9-fold) variations internationally. This study defined a set of indicators reporting on both dimensions to facilitate benchmarking and future interventions aimed at safely reducing antibiotic exposure in early life.
参考来源
- Giannoni E, Dimopoulou V, Klingenberg C, et al. Analysis of Antibiotic Exposure and Early-Onset Neonatal Sepsis in Europe, North America, and Australia. JAMA Netw Open. 2022. PMID: 36416819. doi:10.1001/jamanetworkopen.2022.43691
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。